Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study
ConclusionIn patients prolonging treatment with liraglutide for 5 years, the benefits in relation to metabolic control and CV risk factors are maintained. The UKPDS risk scores suggest that liraglutide is associated with a reduced CHD risk, but not with a reduced stroke risk.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Disease | Italy Health | Statistics | Stroke | Study | UK Health | Victoza